8-isopentyl-butyl-2-(2-furyl)pyrazolo<4,3-e>-1,2,4-triazolo<1,5-c>pyrimidine | 159979-84-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并嘧啶类
• 英文名称: 8-isopentyl-butyl-2-(2-furyl)pyrazolo<4,3-e>-1,2,4-triazolo<1,5-c>pyrimidine
• 英文别名: 8-(3-methyl-1-butyl)-2-(2-furyl)pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine；8-Isopentyl-2-(furan-2-yl)-pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine；8-Isopentyl-2-(2-furyl)-pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine；4-(Furan-2-yl)-11-(3-methylbutyl)-3,5,6,8,10,11-hexazatricyclo[7.3.0.02,6]dodeca-1(12),2,4,7,9-pentaene
• CAS: 159979-84-7
• 化学式: C₁₅H₁₆N₆O
• 分子量: 296.332
• InChiKey: NWEAWDWNMJEULP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  74
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  8-isopentyl-butyl-2-(2-furyl)pyrazolo<4,3-e>-1,2,4-triazolo<1,5-c>pyrimidine 在 10percent aq. HCl 作用下， 反应 3.0h， 生成 4-(5-Furan-2-yl-2H-[1,2,4]triazol-3-yl)-1-(3-methyl-butyl)-1H-pyrazol-3-ylamine
  参考文献：
  名称：

  吡唑并[4,3-e] 1,2,4-三唑并[1,5-c]嘧啶衍生物作为高效和选择性的人A（3）腺苷受体拮抗剂：在N（8）吡唑氮上链的影响。

  摘要：

  先前已经报道了以初步形式（Baraldi等人，J.Med.Chem.1999，42，4473-4478）作为高效和选择性的人A（3）腺苷受体拮抗剂的一系列吡唑并三唑并嘧啶类化合物。合成的化合物显示在亚纳摩尔范围内的A（3）腺苷受体亲和力和在人类A（1），A（2A），A（2B）和A（3）腺苷的放射性配体结合测定中评估的高水平选择性受体。特别是，分析了该链在N（8）吡唑氮上的作用。这项研究使我们能够鉴定出在N（8）吡唑具有甲基的衍生物与在N（5）位置具有4-甲氧基苯基氨基甲酰基部分的衍生物是在亲和力和选择性（hA）方面均具有最佳结合特性的化合物（3）= 0.2 nM，hA（1）/ hA（3）= 5485，hA（2A）/ hA（3）= 6950，hA（2B）/ hA（3）= 1305）。在特定功能模型中，所有化合物均被证明是完全拮抗剂，其中在稳定转染了人A（3）受体的CHO细胞膜中测量了IB-M

  DOI：

  10.1021/jm001047y
• 作为产物：
  描述：

  2-呋喃甲酰肼 以 二苯醚 、 乙二醇甲醚 为溶剂， 反应 1.5h， 生成 8-isopentyl-butyl-2-(2-furyl)pyrazolo<4,3-e>-1,2,4-triazolo<1,5-c>pyrimidine
  参考文献：
  名称：

  Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine Derivatives:  Potent and Selective A_2A Adenosine Antagonists

  摘要：

  A series of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives (10a-o,q,r), bearing alkyl and aralkyl chains on positions 7 and 8, were synthesized in the attempt to obtain potent and selective antagonists for the A(2A) adenosine receptor subtype. The compounds were tested in binding and functional assays to evaluate their potency for the A(2A) compared with the A(1) adenosine receptor subtype. In binding studies in rat brain membranes, most of the compounds showed affinity for A(2A) receptors in the low nanomolar range with a different degree of A(2A) versus A(1) selectivity. Comparison of N-7 (10a-d,h-o)- and N-8 (10e-g)-substituted pyrazolo derivatives indicates that N-7 substitution decreases the A(1) affinity with the concomitant increase of A(2A) selectivity. Specifically, the introduction of a 3-phenylpropyl group at pyrazolo nitrogen in position 7 (101) increased significantly the A(2A) selectivity, being 210-fold, while the A(2A) receptor affinity remained high (K-i = 2.4 nM). With regards to the affinity for A(2A) receptors, also the compound 10n, bearing in the 7-position a beta-morpholin-4-ylethyl group, deserves attention (K-i = 5.6 nM) even though the A(2A) selectivity (84-fold) was not as high as that of 101. Conversely, the compound 10m (N-7-4-phenylbutyl derivative) showed a remarkable selectivity (A(1)/A(2A) ratio = 129) associated with lower A(2A) affinity (K-i = 21 nM). In functional studies, most of the compounds examined reversed 5'-(N-ethylcarbamoyl)adenosine-induced inhibition of rabbit platelet aggregation inhibition which is a biological response mediated by the A(2A) receptor subtype. The compounds are potent and selective A(2A) antagonists which can be useful to elucidate the pathophysiological role of this adenosine receptor subtype. These compounds deserve to be further developed to assess their potential for treatment of neurodegenerative disorders such as Parkinson's disease.

  DOI：

  10.1021/jm950746l

文献信息

• Adenosine A3 receptor modulators
  申请人：——

  公开号：US20030144266A1

  公开（公告）日：2003-07-31

  The compounds of the following formula: 1 wherein R, R 2 , R 3 and A have the meanings given in the specification, are endowed with selective A 3 adenosine receptor antagonist activity. These compounds can be used in a pharmaceutical composition to treat disorders caused by excessive activation of the A 3 receptor, or can be used in a diagnostic application to determine the relative binding of other compounds to the A 3 receptor. The compounds can be labeled, for example with fluorescent or radiolabels, and the labels used in vivo or in vitro to determine the presence of tumor cells which possess a high concentration of adenosine A 3 receptors.

  具有以下公式的化合物：其中R、R2、R3和A具有规范中给定的含义，具有选择性A3腺苷受体拮抗活性。这些化合物可以用于制备药物组合物，用于治疗由A3受体过度激活引起的疾病，也可以用于诊断应用，以确定其他化合物与A3受体的相对结合。这些化合物可以被标记，例如用荧光标记或放射性标记，并且这些标记可以在体内或体外用于确定具有高浓度腺苷A3受体的肿瘤细胞的存在。
• ADENOSINE A3 RECEPTOR MODULATORS
  申请人：Baraldi Giovanni Pier

  公开号：US20070249641A1

  公开（公告）日：2007-10-25

  The compounds of the following formula: wherein R, R 2 , R 3 and A have the meanings given in the specification, are endowed with selective A 3 adenosine receptor antagonist activity. These compounds can be used in a pharmaceutical composition to treat disorders caused by excessive activation of the A 3 receptor, or can be used in a diagnostic application to determine the relative binding of other compounds to the A 3 receptor. The compounds can be labeled, for example with fluorescent or radiolabels, and the labels used in vivo or in vitro to determine the presence of tumor cells which possess a high concentration of adenosine A 3 receptors.

  以下化学式的化合物：其中R、R2、R3和A在说明书中给出的含义，具有选择性A3腺苷受体拮抗活性。这些化合物可以用于制备药物组合物，用于治疗由A3受体过度激活引起的疾病，或者可以用于诊断应用，以确定其他化合物与A3受体的相对结合。这些化合物可以被标记，例如用荧光或放射性标记，并在体内或体外用于确定具有高浓度腺苷A3受体的肿瘤细胞的存在。
• US6407236B1
  申请人：——

  公开号：US6407236B1

  公开（公告）日：2002-06-18
• US6448253B1
  申请人：——

  公开号：US6448253B1

  公开（公告）日：2002-09-10
• US6921825B2
  申请人：——

  公开号：US6921825B2

  公开（公告）日：2005-07-26